Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1

Oncogene

Volumn 30, Issue 36, 2011, Pages 3821-3832

  Takada, Y ^a   Gresh, L ^b,d   Bozec, A ^c   Ikeda, E ^a,e   Kamiya, K ^a   Watanabe, M ^a   Kobayashi, K ^a   Asano, K ^a   Toyama, Y ^a   Wagner, E F ^c   Matsuo, K ^a  

^a KEIO UNIVERSITY   (Japan)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^e YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AP 1; Fra 1; gefitinib; interstitial lung disease; MCP 1; TLR

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; GEFITINIB; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FRA 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE DELETION; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BLOCKING; TRANSGENIC MOUSE;

ANIMALS; CHEMOKINE CCL2; FEMALE; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; LUNG DISEASES, INTERSTITIAL; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-FOS; QUINAZOLINES; TOLL-LIKE RECEPTORS;

MUS; MUS MUSCULUS;

EID: 80052520333     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.101     Document Type: Article

References (51)

1. Aggarwal BB. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745-756. (Pubitemid 41070815)
2. Bakiri L, Takada Y, Radolf M, Eferl R, Yaniv M, Wagner EF et al. (2007). Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bone 40: 867-875. (Pubitemid 46386538)
3. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. (1995). Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 15: 3748-3758.
4. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V et al. (2008). Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454: 221-225. (Pubitemid 351969891)
5. Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M, Wagner EF. (2010). Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 190: 1093-1106.
6. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M et al. (2005). Cellular targets of gefitinib. Cancer Res 65: 379-382.
7. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. (2003). FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306. (Pubitemid 36929716)
8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269. (Pubitemid 46486616)
9. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V et al. (2008). Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 105: 10525-10530.
10. Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L et al. (2004). The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 23: 2789-2799. (Pubitemid 39013551)
11. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868. (Pubitemid 37383716)
12. Finzer P, Soto U, Delius H, Patzelt A, Coy JF, Poustka A et al. (2000). Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumori-genic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition. Oncogene 19: 3235-3244. (Pubitemid 30487410)
13. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246. (Pubitemid 46621858)
14. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784. (Pubitemid 41103588)
15. Guinea-Viniegra J, Zenz R, Scheuch H, Hnisz D, Holcmann M, Bakiri L et al. (2009). TNFα shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev 23: 2663-2674.
16. Han J, Ulevitch RJ. (2005). Limiting inflammatory responses during activation of innate immunity. Nat Immunol 6: 1198-1205. (Pubitemid 43045628)
17. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y et al. (2003). Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139. (Pubitemid 36092019)
18. Ishii Y, Fujimoto S, Fukuda T. (2006). Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 174: 550-556. (Pubitemid 44330548)
19. Ishizaka A, Watanabe M, Yamashita T, Ogawa Y, Koh H, Hasegawa N et al. (2001). New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 29: 896-898. (Pubitemid 32299735)
20. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. (2005). Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173-1179. (Pubitemid 43093664)
21. Jochum W, David JP, Elliott C, Wutz A, Plenk Jr H, Matsuo K et al. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6: 980-984.
22. Johnson GB, Brunn GJ, Platt JL. (2004). Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 172: 20-24. (Pubitemid 38020450)
23. Katzenstein AL, Myers JL. (1998). Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157: 1301-1315.
24. Kawai T, Akira S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
25. Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M et al. (2005). Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288: L342-L349. (Pubitemid 40105373)
26. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158. (Pubitemid 37432975)
27. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH et al. (2010). Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 16: 1307-1314.
28. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
29. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. (2000). Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24: 184-187. (Pubitemid 30094722)
30. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocar-cinoma. N Engl J Med 361: 947-957.
31. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. (2006). Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26: 430-437. (Pubitemid 44632271)
32. Morishita H, Saito F, Kayama H, Atarashi K, Kuwata H, Yamamoto M et al. (2009). Fra-1 negatively regulates lipopolysaccharide-mediated inflammatory responses. Int Immunol 21: 457-465.
33. Paine III R, Rolfe MW, Standiford TJ, Burdick MD, Rollins BJ, Strieter RM. (1993). MCP-1 expression by rat type II alveolar epithelial cells in primary culture. J Immunol 150: 4561-4570. (Pubitemid 23133733)
34. Peters-Golden M, Thebert P. (1987). Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages. Am Rev Respir Dis 135: 1020-1026. (Pubitemid 18021484)
35. Pircher A, Ploner F, Popper H, Hilbe W. (2010). Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 69: 265-271.
36. Ray N, Kuwahara M, Takada Y, Maruyama K, Kawaguchi T, Tsubone H et al. (2006). c-Fos suppresses systemic inflammatory response to endotoxin. Int Immunol 18: 671-677. (Pubitemid 43779057)
37. Rollins BJ. (1997). Chemokines. Blood 90: 909-928. (Pubitemid 27314123)
38. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T. (2006). Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176: 1899-1907. (Pubitemid 43134335)
39. Suzuki H, Aoshiba K, Yokohori N, Nagai A. (2003). Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63: 5054-5059. (Pubitemid 37025129)
40. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. (2004). Genetic deletion of glycogen synthase kinase-3b abrogates activation of IkBa kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279: 39541-39554. (Pubitemid 39258221)
41. Takada Y, Ray N, Ikeda E, Kawaguchi T, Kuwahara M, Wagner EF et al. (2010). Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kB. J Immunol 184: 1014-1021.
42. Tallquist MD, Soriano P. (2000). Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis 26: 113-115. (Pubitemid 30158091)
43. Toney LM, Cattoretti G, Graf JA, Merghoub T, Pandolfi PP, Dalla-Favera R et al. (2000). BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol 1: 214-220.
44. Ulich TR, Watson LR, Yin SM, Guo KZ, Wang P, Thang H et al. (1991). The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am J Pathol 138: 1485-1496.
45. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA et al. (2007). Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13: 1042-1049. (Pubitemid 47517513)
46. Watanabe M, Ishizaka A, Ikeda E, Ohashi A, Kobayashi K. (2003). Contributions of bronchoscopic microsampling in the supplemental diagnosis of small peripheral lung carcinoma. Ann Thorac Surg 76: 1668-1673.
47. Wolter S, Doerrie A, Weber A, Schneider H, Hoffmann E, von der Ohe J et al. (2008). c-Jun controls histone modifications, NF-κB recruitment and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol 28: 4407-4423. (Pubitemid 351904962)
48. Yamaguchi T, Takada Y, Maruyama K, Shimoda K, Arai Y, Nango N et al. (2009). Fra-1/AP-1 impairs inflammatory responses and chondrogenesis in fracture healing. J Bone Miner Res 24: 2056-2065.
49. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D et al. (2005). Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437: 369-375. (Pubitemid 41613493)
50. Zhang Q, Adiseshaiah P, Kalvakolanu DV, Reddy SP. (2006). A phosphatidylinositol 3-kinase-regulated Akt-independent signaling promotes cigarette smoke-induced FRA-1 expression. J Biol Chem 281: 10174-10181. (Pubitemid 43864553)
51. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T et al. (2006). Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4: 111-121. (Pubitemid 44138718)